| Investment Objective The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved. |
|||||||||||||
| Date of inception/allotment |
28th June, 1999 | ||||||||||||
| Fund Manager |
Mr. Kamal Gada B.Com, CA, CS, CFA Managing the scheme since May 2022 Total Exp: 18 Yrs |
||||||||||||
| Fund AUM/Folio as on 31st July, 2026 |
Fund Size Monthly Average : 1,337.39 Crore Closing AUM : 1,370.92 Crore No. of Folios : 65,566 |
||||||||||||
| High/Low NAV in the month |
High Growth Option : 335.2331 Low Growth Option : 323.6335 |
||||||||||||
Month-end Total Expense Ratio (%)* |
Regular : 2.22 Direct : 1.28 *For detailed YTD Total Expense Ratio refer to Click Here |
||||||||||||
Minimum Investment Amount |
Minimum initial investment of 5000/-and in multiples of 1/- thereafter with no upper limit. | ||||||||||||
Plans/Options
(Regular / Direct) |
Growth option IDCW option with Payout and Reinvestment | ||||||||||||
Market Capitalisation (%) |
|
||||||||||||
Load Structure |
Entry Load : Nil Exit Load : < 30 days – 1%;≥ 30 days – Nil |
||||||||||||
NAV per unit as on 31st July, 2026 |
Regular Growth Option 334.5099 Regular IDCW Option 258.5294 Direct Growth Option 380.9617 Direct IDCW Option 294.4555 |
||||||||||||
Benchmark Index |
BSE Healthcare TRI | ||||||||||||
Overweight (Top 5) |
% of Nav |
Underweight (Top 5) |
% of Nav |
| Ajanta Pharma Ltd | 3.9 | Sun Pharmaceuticals Industries Ltd | -4.6 |
| Caplin Point Laboratories Ltd | 3.6 | Torrent Pharmaceuticals Ltd | -4.5 |
| Gland Pharma Ltd | 2.3 | Laurus Labs Ltd | -4.3 |
| Proctor & Gamble Health Ltd | 2.1 | Cipla Ltd | -3.6 |
| Global Health Ltd | 2.1 | Max Healthcare Institute Ltd | -2.3 |
UTI Healthcare Fund (Formerly known as UTI Pharma & Healthcare Fund) IDCW Declared |
||||||
Year |
IDCW |
Per unt |
NAV (Cum Div ) |
Face Value (per unit) |
NAV Date |
Record Date |
2006 |
25% |
2.50 |
21.34 |
10.00 |
10-01-2006 |
17-01-2006 |
2008 |
15% |
1.50 |
20.91 |
10.00 |
26-08-2008 |
02-09-2008 |
2010 |
17% |
1.70 |
32.65 |
10.00 |
28-10-2010 |
04-11-2010 |
The scheme IDCW details under regular plan.
Disclaimer:Pursuant to payment of Dividend/Bonus, the Nav of the income distribution cum capital withdrawal options of the schemes would fall to the extent of payout and statutory levy (if applicable)
| Healthcare | 94% |
| Chemicals | 2% |
|
Equity
|
% of NAV
|
| Sun Pharmaceuticals Industries Ltd. | 8.71 |
| Divis Laboratories Ltd. | 5.57 |
| Ajanta Pharma Ltd. | 4.80 |
| Caplin Point Laboratories Ltd | 3.95 |
| Lupin Ltd. | 3.59 |
| Gland Pharma Ltd | 3.56 |
| Apollo Hospitals Enterprise Ltd. | 3.46 |
| Dr Reddy'S Laboratories Ltd. | 3.10 |
| Alkem Laboratories Ltd | 3.10 |
| Global Health Ltd. | 2.81 |
| Max Healthcare Institute Ltd | 2.76 |
| IPCA Laboratories Ltd. | 2.68 |
| Fortis Healthcare Ltd. | 2.58 |
| Anthem Biosciences Ltd | 2.50 |
| Proctor & Gamble Health Ltd | 2.41 |
| Rainbow Childrens Medicare Ltd | 2.34 |
| Sai Life Sciences Ltd | 2.20 |
| Jupiter Life Line Hospitals Ltd | 2.18 |
| Cohance Lifesciences Ltd. | 2.17 |
| Marksans Pharma Ltd. | 2.17 |
| Glenmark Pharmaceuticals Ltd | 2.11 |
| Viyash Scientific Ltd | 1.98 |
| Aster DM Quality Care Ltd. | 1.94 |
| Aurobindo Pharma Ltd. | 1.84 |
| Sudeep Pharma Ltd. | 1.71 |
| Dr. Lal Pathlabs Ltd. | 1.67 |
| Metropolis Healthcare Ltd | 1.64 |
| Cipla Ltd. | 1.61 |
| Biocon Ltd. | 1.55 |
| Eris Lifesciences Ltd | 1.33 |
| Others | 13.04 |
| Net Current Assets | 2.92 |
| Total | 100.00 |
% of top 10 stocks |
42.65 |
Median Market Cap ( Cr) |
43,891 |
Weighted Average Market Cap |
94,534 |
Number of Securities |
44 |
All figures given are provisional and unaudited. |
Quantitative Indicators |
Fund |
Benchmark |
Beta |
0.92 |
1 |
Standard Deviation (Annual) |
13.40% |
14.08% |
Sharpe ratio |
1.33 |
|
Portfolio Turnover Ratio (Annual) |
0.28 |
|
P/B |
5.45 |
5.35 |
P/E |
42.63 |
42.98 |
RoE |
15.36 |
15.78 |
Calculation Methodology: P/E and P/B are based on harmonic mean: ROE is calculated as a weighted average. All figures are based on trailing twelve months (TTM) data.
| Fund Performance Vs Benchmark (CAGR) as on 31st July, 2026 Growth of 10000 |
||||||
| Period | NAV Growth (%) |
BSE Healthcare TRI (%) |
Nifty 50 TRI (%) |
NAV Growth () |
BSE Healthcare TRI () |
Nifty 50 TRI () |
| 1 Y | 12.75 | 12.53 | -0.43 | 11,275 | 11,253 | 9,957 |
| 3 Y | 23.19 | 23.02 | 8.56 | 18,706 | 18,628 | 12,797 |
| 5 Y | 14.70 | 14.91 | 10.40 | 19,860 | 20,043 | 16,404 |
| 10 Y | 13.55 | 12.74 | 12.28 | 35,659 | 33,195 | 31,864 |
| SI* | 15.00 | 15.25 | N.A | 4,42,073 | 4,68,879 | N.A |
B - Benchmark, AB - Additional Benchmark, TRI - Total Return Index. Past performance may or may not be sustained in future. Different plans shall have different expense structures. The performance details provided herein are of regular plan (growth Option). Returns greater than 1 year period are Compound Annual Growth Rate (CAGR). *Inception Date of UTI Healthcare Fund: June 28, 1999. @Since Inception return for SIP – Aug 1, 2007. For SIP calculation monthly investment of `10000 is taken. The Schemes is Managed by Mr. Kamal Gada since May-2022. Period for which scheme’s performance has been provided is computed basis last day of the monthend preceding the date of advertisement. Load is not taken into consideration for computation of performance.
| Period | |||||||
|
Investment Amount ()
|
Fund Value
() |
BSE
Healthcare TRI () |
Nifty 50 TRI ()
|
Yield (%) Fund
|
Yield (%)
BSE Healthcare TRI |
Yield (%)
Nifty 50 TRI |
|
| 1 Y | 1,20,000 | 1,38,477 | 1,38,184 | 1,19,609 | 29.88 | 29.39 | -0.61 |
| 3 Y | 3,60,000 | 4,80,513 | 4,78,078 | 3,84,933 | 19.71 | 19.35 | 4.40 |
| 5 Y | 6,00,000 | 10,01,472 | 10,02,049 | 7,36,945 | 20.62 | 20.64 | 8.16 |
| 7 Y | 8,40,000 | 17,58,518 | 17,68,670 | 12,67,635 | 20.75 | 20.91 | 11.56 |
| 10 Y | 12,00,000 | 31,52,492 | 31,06,124 | 22,36,430 | 18.37 | 18.09 | 11.97 |
| 15 Y | 18,00,000 | 66,01,798 | 65,75,871 | 48,87,346 | 15.79 | 15.74 | 12.31 |
| SI | 26,00,000 | 1,83,05,580 | 1,91,53,434 | 1,15,48,740 | 15.55 | 15.88 | 12.14 |
Note: Systematic Investment Plan (SIP) returns are worked out assuming investment of 10,000/- every month at NAV per unit of the scheme as on the first working day for the respective time periods. The loads have not been taken into account. Past performance may or may not be sustained in future.
This product is suitable for investors who are seeking*:
- Long term capital appreciation
- Investment predominantly in equity and equity related securities in the Healthcare Services Sector
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.